查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1372733

女性避孕市场 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按避孕药物、设备、地区、竞争预测和机会细分，2018-2028F

Female Contraceptive Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Contraceptive Drugs, By Device, By Region, By Competition Forecast & Opportunities, 2018-2028F
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022年，全球女性避孕药市场估值达150.1亿美元，预计在预测期内将显着成长，预计到2028年复合年增长率(CAGR)为6.24%。全球女性避孕药市场包括生产分发专为女性设计的各种避孕产品和装置，以防止意外怀孕。这个市场长期以来一直是妇女保健和计划生育措施的重要组成部分。

主要市场驱动因素

妇女赋权

市场概况
预测期 2024-2028
2022 年市场规模 150.1亿美元
2028 年市场规模 216.3亿美元
2023-2028 年复合年增长率 6.24%
成长最快的细分市场 口服避孕药
最大的市场 北美洲

妇女赋权是社会变革和进步的驱动力，其影响力扩大到包括医疗保健在内的各个领域。全球女性避孕药具市场对于生殖健康和计划生育至关重要，受到妇女赋权的显着影响。妇女赋权包括向妇女提供有关生殖健康和避孕选择的资讯和教育。当女性了解情况时，她们可以根据个人目标、健康需求和生活方式做出明智的避孕选择。赋权往往伴随着获得医疗服务的机会的改善。有权势的女性更有可能寻求医疗保健资源，包括计划生育诊所和避孕措施。这种需求的增加可以刺激市场成长，促使製药公司投资于新的和改进的避孕选择的研发。经济独立和赋权使妇女能够负担得起避孕药具和计划生育服务。财务自主权使她们能够对自己的生殖健康做出选择，而不必只依赖伴侣或家庭成员。这种财务自由有助于增加避孕药具的使用和市场的成长。获得权力的女性更有可能挑战和改变有关避孕和计划生育的社会规范和态度。透过倡导生殖权利并打破与避孕药具使用相关的耻辱，女性赋权可以为那些寻求避孕药具的人创造一个更具支持性的环境。赋权通常会带来倡议和行动。赋予妇女权力和致力于妇女权利的组织可以推动有关计划生育和避孕药具重要性的宣传活动。此类措施有助于教育和激励个人将避孕视为可行的选择。被赋权的女性常常成为所在社区的榜样。当他们做出有关避孕的明智决定时，可以激励其他人也这样做。这种连锁反应可能会导致社区和地区对避孕药具的更高需求。

人口成长和都市化

多年来，全球女性避孕市场显着成长，而这项扩张的关键驱动因素是人口成长和都市化之间的相互作用。随着世界人口持续增加，居住在城市地区的人口比例不断增加，对有效计划生育和女性避孕药具的需求激增。都市化伴随着医疗保健服务的改善。在城市地区，个人通常更容易前往诊所、医院和计划生育中心，那里提供避孕药具。这些服务的邻近性鼓励更多的人，尤其是妇女，寻求和使用避孕药具。由于居住空间有限、生活成本上升和职业抱负等因素，城市化往往导致家庭规模缩小。随着城市家庭优先考虑更小、更易于管理的家庭规模，对有效避孕药具的计划和间隔生育的需求更大。城市地区通常拥有更好的教育基础设施，从而提高人们对计划生育和避孕方法重要性的认识。城市中心的人们更有可能了解自己的生殖健康选择，因此选择使用女性避孕药来防止意外怀孕。城市化往往带来经济机会和更高的生活水准。随着城市地区的个人和家庭努力实现财务稳定和职业发展，他们倾向于推迟生育并优先考虑避孕，作为计划生育和确保经济未来的手段。城市环境往往促进性别平等和妇女赋权，使妇女能够对其生殖健康做出选择。获得权力的女性更有可能寻求和使用避孕药具，从而促进女性避孕药具市场的成长。

改变社会规范

全球女性避孕市场正在不断发展，这不仅受到技术和医疗保健进步的推动，而且还受到社会规范和避孕态度转变的推动。随着世界各地社会的不断发展，人们对计划生育和生殖健康的看法也不断发展。社会规范的改变正在逐渐减少与避孕相关的耻辱。在许多社会，有关计划生育和避孕药具使用的讨论一度被视为禁忌。然而，随着对话变得更加开放和接受，人们越来越愿意寻求避孕选择，从而推动市场成长。社会规范的改变往往伴随着妇女赋权的发生。随着女性对自己的生活（包括生育选择）拥有更大的控制权，她们更有可能寻求和使用避孕药。赋权妇女正在倡导她们的生殖权利和选择，从而促进了对女性避孕药具的需求增加。社会变革催生了促进计划生育和生殖健康的教育措施。这些计划旨在让女性和男性了解避孕选择、福利和负责任的计划生育做法。更多知识鼓励避孕药具的使用，进而促进市场成长。规范的改变，例如推迟生育以专注于职业或个人目标，导致对避孕药具的需求增加。夫妇们积极选择推迟建立家庭，直到他们在经济和情感上做好准备。这种延迟通常需要有效的避孕措施。

全球健康议题

全球健康议题一直是各个医疗保健产业发展和扩张的驱动力，全球女性避孕市场也不例外。人们对人口控制、预防意外怀孕和性传染感染（STI）传播的认识不断增强，推动了女性避孕市场的创新。推动女性避孕市场成长的主要全球健康问题之一是有效控制人口的需要。随着世界人口持续激增，特别是在发展中国家，人们越来越意识到这对资源、医疗保健系统和环境造成的压力。世界各地的政策制定者和医疗保健组织都认识到赋予妇女计划生育选择权的重要性。女性避孕药具提供了控製家庭规模的可靠方法，使女性能够根据自己的喜好和情况计划怀孕并间隔怀孕。这不仅可以让家庭更加健康，还有助于遏制人口过剩，这是许多国家面临的关键问题。因此，女性避孕药具的供应和可近性已成为各国政府和国际卫生组织的优先事项，推动了市场成长。意外怀孕可能会产生深远的社会、经济和健康后果。它们可能导致教育延迟、职业机会受到限制、经济压力增加，甚至孕产妇和婴儿死亡率更高。

主要市场挑战

访问和意识有限

全球女性避孕药具市场面临的最重大挑战之一是取得和意识有限，特别是在低收入和边缘化社区。由于地理、经济或文化障碍，世界各地的许多妇女仍然无法获得负担得起且可靠的避孕药。在某些情况下，女性根本不知道可用的避孕方法及其好处。

耻辱和文化障碍

文化和社会规范可能会对避孕药具的使用造成重大障碍，尤其是在保守或传统社会中。围绕避孕的耻辱和对判断的恐惧可能会阻止女性寻求和使用避孕药具。这些文化障碍往往根深蒂固，需要采取全面的策略来解决。

为了消除耻辱和文化障碍，教育和宣传活动至关重要。这些努力旨在改变社会对避孕的看法和态度，同时强调其在促进计划生育和妇女健康方面的重要性。当地社区的参与和文化敏感的方法对于应对这些挑战也至关重要。

产品安全和副作用

女性避孕市场面临的另一个挑战是对产品安全和潜在副作用的担忧。虽然避孕药具通常安全有效，但有些女性可能会出现副作用或不良反应。对这些副作用的恐惧可能会阻止一些女性使用避孕药具。

为了应对这项挑战，製药公司和医疗保健提供者正在不断研究和开发安全性更高、副作用更少的新避孕方法。此外，医疗保健专业人员正在努力为女性提供更好的咨询和支持，帮助她们根据个人健康和偏好做出避孕选择的明智决定。

主要市场趋势

副作用减少的荷尔蒙避孕药

女性避孕药市场最有前景的趋势之一是开发副作用减少的荷尔蒙避孕药。製药公司正在投资研究开发避孕药，以有效预防怀孕，同时最大限度地减少体重增加、情绪波动和性慾下降等常见副作用。这些创新旨在改善整体用户体验，并鼓励更多女性选择荷尔蒙避孕药作为首选方法。

长效可逆避孕药 (LARC)

长效可逆避孕药 (LARC) 作为一种方便、有效的女性选择而越来越受欢迎。 LARC 包括子宫内避孕器 (IUD) 和植入式避孕器，只需一次插入即可避孕数年。随着女性寻求适合她们忙碌生活方式的可靠、低维护的避孕选择，这一趋势预计将持续下去。

数位健康和​​避孕应用程式

数位健康和​​科技融入女性避孕市场是一个值得注意的趋势。智慧型手机应用程式和穿戴式装置正在开发中，以帮助女性追踪月经週期和生育能力，为自然计划生育方法提供有价值的资讯。这些应用程式提供了便利，并且可以与传统避孕方法一起使用以增加保证。

可持续且环保的避孕药具

随着环保意识的不断增强，永续和环保的避孕选择出现了新兴趋势。製造商正在探索可生物降解的材料和包装，以减少与避孕产品相关的浪费。此外，重点是开发环境足迹最小的避孕药。

细分市场洞察

避孕药见解

根据避孕药类别，由于几个令人信服的原因，口服避孕药细分市场将在 2022 年成为全球女性避孕药市场的主导者。首先也是最重要的是，它们提供了一种方便且被广泛接受的节育方法，使女性能够透过简单的每日药丸来掌控自己的生殖健康。这种易用性符合许多女性在当今忙碌而忙碌的生活方式。此外，口服避孕药具有良好的安全性记录和相对较低的副作用发生率，使其成为广大女性值得信赖的选择。此外，正在进行的研究和开发工作继续完善这些药物，解决减少副作用和提高疗效等问题。组合药丸和纯黄体素药丸的可用性进一步满足个人喜好和医疗需求。随着全球医疗保健服务的普及和计划生育意识的提高，口服避孕药可能会保持其在全球市场的主导地位，为女性提供可靠且适应性强的避孕选择。

设备洞察

由于多种因素，包括意外怀孕发生率上升、临床疗效高以及在人群中广泛采用，预计女性避孕植入剂市场将出现成长。在皮下植入避孕剂类别中，预计依托孕烯植入剂将大幅扩张。依托孕烯是一种抑制排卵的激素，也会引起子宫颈黏液和子宫内膜的变化，使精子到达子宫和受精卵附着变得更加困难。皮下依托孕烯植入剂被用作避孕方法来防止怀孕，药物包含在插入上臂皮肤下方的小塑胶棒中。棒子逐渐将药物释放到体内，提供长达三年的连续避孕效果。预计在预测期内，公司越来越注重实施各种业务策略，例如推出新产品、扩大不同国家的产品供应、进行合併和进行公司分拆，预计该市场的成长将进一步推动。

区域洞察

预计在整个预测期内，北美将保持其在女性避孕器具市场的主导地位，这主要是由于几个因素。其中包括意外怀孕和高堕胎率的增加、先进的医疗基础设施的存在、避孕药物和设备的高采用率以及越来越多的政府倡议。美国和加拿大的女性人口中有很大一部分属于育龄群体。因此，意外怀孕和堕胎率的上昇在推动该地区市场扩张方面发挥关键作用。例如，古特马赫研究所2022年3月的资料显示，2015年至2019年间，北美每年总共有566万例怀孕，其中259万例意外怀孕，88.6万例堕胎。此外，皮尤研究中心2022 年6 月发布的统计数据显示，美国堕胎案件有所增加，2020 年美国有930,160 起，而2019 年为916,460 起。预计堕胎案件的激增将推动对各种避孕方法的需求防止意外怀孕，进而推动市场成长。

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：客户之声

第 5 章：全球女性避孕市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依避孕药（口服避孕药、避孕针剂、外用避孕药、杀精剂）
    • 依装置分类（女用保险套、隔膜和帽子、阴道环、避孕海绵、皮下避孕植入物、子宫内避孕装置 (IUCD) 等）
    • 按地区
    • 按公司划分 (2022)
  • 产品市场地图
    • 透过避孕药
    • 按设备
    • 按地区

第 6 章：北美女性避孕市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依避孕药（口服避孕药、避孕针剂、外用避孕药、杀精剂）
    • 依装置分类（女用保险套、隔膜和帽子、阴道环、避孕海绵、皮下避孕植入物、子宫内避孕装置 (IUCD) 等）
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 7 章：欧洲女性避孕市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依避孕药（口服避孕药、避孕针剂、外用避孕药、杀精剂）
    • 依装置分类（女用保险套、隔膜和帽子、阴道环、避孕海绵、皮下避孕植入物、子宫内避孕装置 (IUCD) 等）
    • 按国家/地区
  • 欧洲：国家分析
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙

第 8 章：亚太地区女性避孕市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依避孕药（口服避孕药、避孕针剂、外用避孕药、杀精剂）
    • 依装置分类（女用保险套、隔膜和帽子、阴道环、避孕海绵、皮下避孕植入物、子宫内避孕装置 (IUCD) 等）
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国

第 9 章：南美洲女性避孕市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依避孕药（口服避孕药、避孕针剂、外用避孕药、杀精剂）
    • 依装置分类（女用保险套、隔膜和帽子、阴道环、避孕海绵、皮下避孕植入物、子宫内避孕装置 (IUCD) 等）
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 10 章：中东和非洲女性避孕市场展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依避孕药（口服避孕药、避孕针剂、外用避孕药、杀精剂）
    • 依装置分类（女用保险套、隔膜和帽子、阴道环、避孕海绵、皮下避孕植入物、子宫内避孕装置 (IUCD) 等）
    • 按国家/地区
  • MEA：国家分析
    • 南非女性避孕
    • 沙乌地阿拉伯 女性避孕
    • 阿联酋女性避孕
    • 科威特女性避孕

第 11 章：市场动态

  • 司机
  • 挑战

第 12 章：市场趋势与发展

  • 近期发展
  • 併购
  • 产品发布

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • 商业概览
  • 产品供应
  • 最近的发展
  • 财务（据报导）
  • 主要人员
  • SWOT分析
    • Bayer AG
    • Mayer Laboratories Inc
    • Pfizer Inc
    • Mylan Pharmaceuticals Inc
    • Teva Pharmaceutical Industries Ltd
    • Organon & Co.
    • Agile Therapeutics Inc
    • Lupin Pharmaceuticals Inc
    • The Female Health Company
    • FUJI LATEX CO.,LTD.

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 16167

In 2022, the Global Female Contraceptive Market achieved a valuation of USD 15.01 billion and is poised for remarkable growth in the projected period, with an expected Compound Annual Growth Rate (CAGR) of 6.24% through 2028. The global female contraceptive market encompasses the production and distribution of a diverse range of contraceptive products and devices tailored for women to prevent unintended pregnancies. This market has long been an essential element of women's healthcare and family planning initiatives.

Key Market Drivers

Women's Empowerment

Market Overview
Forecast Period2024-2028
Market Size 2022USD 15.01 Billion
Market Size 2028USD 21.63 Billion
CAGR 2023-20286.24%
Fastest Growing SegmentOral Contraceptives
Largest MarketNorth America

Women's empowerment is a driving force for social change and progress, extending its influence on various sectors, including healthcare. The global female contraceptive market, vital for reproductive health and family planning, is significantly impacted by women's empowerment. Women's empowerment involves providing women with information and education about their reproductive health and contraceptive options. When women are well-informed, they can make informed choices about contraception that align with their personal goals, health needs, and lifestyles. Empowerment often comes with improved access to healthcare services. Empowered women are more likely to seek out healthcare resources, including family planning clinics and contraception. This increased demand can stimulate market growth, prompting pharmaceutical companies to invest in research and development of new and improved contraceptive options. Economic independence and empowerment enable women to afford contraceptives and family planning services. Financial autonomy allows them to make choices about their reproductive health without relying solely on their partners or family members. This financial freedom contributes to increased contraceptive usage and market growth. Empowered women are more likely to challenge and change societal norms and attitudes surrounding contraception and family planning. By advocating for reproductive rights and breaking down stigmas associated with contraceptive use, empowered women can create a more supportive environment for those seeking contraceptives. Empowerment often leads to advocacy and activism. Empowered women and organizations dedicated to women's rights can drive awareness campaigns about family planning and the importance of contraceptives. Such initiatives help educate and motivate individuals to consider contraception as a viable option. Empowered women often serve as role models within their communities. When they make informed decisions about contraception, it can inspire others to do the same. This ripple effect can contribute to a higher demand for contraceptives within communities and regions.

Growing Population and Urbanization

The global female contraceptive market has seen significant growth over the years, and one key driver of this expansion is the interplay between population growth and urbanization. As the world's population continues to increase, with a growing proportion residing in urban areas, the demand for effective family planning and female contraceptives has surged. Urbanization is accompanied by improved access to healthcare services. In urban areas, individuals often have easier access to clinics, hospitals, and family planning centers where contraceptive options are readily available. The proximity of these services encourages more people, especially women, to seek and use contraceptives. Urbanization often leads to smaller family sizes due to factors such as limited living space, higher living costs, and career aspirations. As urban families prioritize smaller and more manageable family sizes, there is a greater demand for effective contraceptives to plan and space births. Urban areas typically have better educational infrastructure, leading to increased awareness about the importance of family planning and contraceptive methods. People in urban centers are more likely to be informed about their reproductive health options and, as a result, choose to use female contraceptives to prevent unplanned pregnancies. Urbanization often brings about economic opportunities and higher standards of living. As individuals and families in urban areas strive for financial stability and career advancement, they tend to delay childbirth and prioritize contraception as a means of family planning and securing their economic future. Urban environments often promote gender equality and women's empowerment, enabling women to make choices about their reproductive health. Empowered women are more likely to seek and use contraceptives, contributing to the growth of the female contraceptive market.

Changing Social Norms

The global female contraceptive market is evolving, driven not only by advancements in technology and healthcare but also by shifting social norms and attitudes towards contraception. As societies around the world continue to evolve, so do the perceptions of family planning and reproductive health. Changing social norms is gradually reducing the stigma associated with contraception. In many societies, discussions surrounding family planning and contraceptive use were once considered taboo. However, as conversations become more open and accepting, individuals are increasingly comfortable seeking contraceptive options, thus driving market growth. Changing social norms often accompany the empowerment of women. As women gain greater control over their lives, including their reproductive choices, they are more likely to seek and use contraceptives. Empowered women are advocating for their reproductive rights and choices, contributing to an increased demand for female contraceptives. Societal changes have led to educational initiatives that promote family planning and reproductive health. These programs aim to inform both women and men about contraceptive options, benefits, and responsible family planning practices. Greater knowledge encourages the use of contraceptives, which boosts market growth. Changing norms, such as delaying parenthood to focus on careers or personal goals, have resulted in a higher demand for contraceptives. Couples are actively choosing to postpone starting families until they feel financially and emotionally prepared. This delay often requires effective contraception.

Global Health Concerns

Global health concerns have been a driving force behind the development and expansion of various healthcare sectors, and the global female contraceptive market is no exception. The growing awareness of population control, the prevention of unintended pregnancies, and the spread of sexually transmitted infections (STIs) has fueled innovation in the female contraceptive market. One of the primary global health concerns that have driven the growth of the female contraceptive market is the need for effective population control. As the world's population continues to surge, particularly in developing countries, there is a growing awareness of the strain this puts on resources, healthcare systems, and the environment. Policymakers and healthcare organizations worldwide recognize the importance of empowering women with choices for family planning. Female contraceptives offer a reliable means of controlling family size, allowing women to plan pregnancies and space them according to their preferences and circumstances. This not only leads to healthier families but also helps in curbing overpopulation, a critical issue facing many countries. The availability and accessibility of female contraceptives have thus become a priority for governments and international health organizations, driving market growth. Unintended pregnancies can have far-reaching social, economic, and health consequences. They can result in delayed education, restricted career opportunities, increased financial stress, and even higher rates of maternal and infant mortality.

Key Market Challenges

Limited Access and Awareness

One of the most significant challenges facing the global female contraceptive market is limited access and awareness, particularly in low-income and marginalized communities. Many women around the world still lack access to affordable and reliable contraceptives due to geographical, financial, or cultural barriers. In some cases, women are simply unaware of the available contraceptive options and their benefits.

To overcome this challenge, efforts are being made to improve education and awareness about contraceptives, especially in underserved regions. NGOs, governments, and international organizations are working together to increase access to family planning services, ensuring that women have the information and resources they need to make informed decisions about their reproductive health.

Stigma and Cultural Barriers

Cultural and societal norms can create significant barriers to contraceptive use, especially in conservative or traditional societies. Stigma surrounding contraception and the fear of judgment can deter women from seeking and using contraceptives. These cultural barriers are often deeply rooted and require comprehensive strategies to address.

To combat stigma and cultural barriers, education and advocacy campaigns are essential. These efforts aim to change societal perceptions and attitudes toward contraception while emphasizing its importance in promoting family planning and women's health. Local community engagement and culturally sensitive approaches are also crucial in addressing these challenges.

Product Safety and Side Effects

Another challenge faced by the female contraceptive market is concerns related to product safety and potential side effects. While contraceptives are generally safe and effective, some women may experience side effects or adverse reactions. The fear of these side effects can discourage some women from using contraceptives.

To address this challenge, pharmaceutical companies and healthcare providers are continually researching and developing new contraceptive methods with improved safety profiles and fewer side effects. Additionally, healthcare professionals are working to provide better counseling and support to women, helping them make informed decisions about contraceptive options based on their individual health and preferences.

Key Market Trends

Hormonal Contraceptives with Reduced Side Effects

One of the most promising trends in the female contraceptive market is the development of hormonal contraceptives with reduced side effects. Pharmaceutical companies are investing in research to create contraceptives that offer effective pregnancy prevention while minimizing common side effects like weight gain, mood swings, and decreased libido. These innovations are aimed at improving the overall user experience and encouraging more women to choose hormonal contraceptives as their preferred method.

Long-Acting Reversible Contraceptives (LARCs)

Long-Acting Reversible Contraceptives (LARCs) are gaining popularity as a convenient and effective option for women. LARCs include intrauterine devices (IUDs) and contraceptive implants, which can provide contraception for several years with a single insertion. This trend is expected to continue as women seek reliable, low-maintenance contraceptive options that fit their busy lifestyles.

Digital Health and Contraceptive Apps

The integration of digital health and technology into the female contraceptive market is a noteworthy trend. Smartphone applications and wearable devices are being developed to help women track their menstrual cycles and fertility, providing valuable information for natural family planning methods. These apps offer convenience and can be used alongside traditional contraceptive methods for added assurance.

Sustainable and Eco-Friendly Contraceptives

As environmental awareness continues to grow, there is an emerging trend toward sustainable and eco-friendly contraceptive options. Manufacturers are exploring biodegradable materials and packaging, reducing waste associated with contraceptive products. Additionally, there is a focus on developing contraceptives with a minimal environmental footprint.

Segmental Insights

Contraceptive Drugs Insights

Based on the category of Contraceptive Drugs, the Oral Contraceptives segment emerged as the dominant player in the global market for female contraceptive market in 2022 for several compelling reasons. First and foremost, they offer a convenient and widely accepted method of birth control, allowing women to take charge of their reproductive health with a simple daily pill. This ease of use aligns with the busy and on-the-go lifestyles of many women today. Additionally, oral contraceptives have a well-established safety record and a relatively low incidence of side effects, making them a trusted choice for a broad spectrum of women. Moreover, ongoing research and development efforts continue to refine these medications, addressing concerns such as reducing side effects and increasing efficacy. The availability of both combination pills and progestin-only pills further caters to individual preferences and medical needs. As access to healthcare services and awareness of family planning grow worldwide, oral contraceptives are likely to maintain their dominance in the global market, offering a reliable and adaptable contraceptive option for women.

Device Insights

Anticipated growth in the female contraceptive market is expected within the sub-dermal contraceptive implants category due to several factors, including a rising incidence of unintended pregnancies, high clinical efficacy, and widespread adoption among the population. Within the sub-dermal contraceptive implants category, it is foreseen that Etonogestrel implants will experience substantial expansion. Etonogestrel, a hormone that inhibits ovulation, also induces changes in cervical mucus and the uterine lining, making it more challenging for sperm to reach the uterus and for a fertilized egg to attach. Subdermal Etonogestrel implants are employed as a contraceptive method to prevent pregnancy, with the medication contained in a small plastic rod inserted beneath the skin of the upper arm. This rod gradually releases the medication into the body, providing continuous contraception for up to three years. The market's growth is further expected to receive a boost from the increasing focus of companies on implementing various business strategies, such as launching new products, expanding product availability in different countries, engaging in mergers, and undertaking company spin-offs, during the forecast period.

Regional Insights

North America is projected to maintain its dominance in the female contraceptive devices market throughout the forecast period, primarily due to several factors. These include the increasing instances of unintended pregnancies and high abortion rates, the presence of advanced healthcare infrastructure, a high rate of adoption of contraceptive drugs and devices, and a growing number of government initiatives. A significant portion of the female population in the United States and Canada falls within the reproductive age group. Consequently, the rising occurrences of unwanted pregnancies and abortion rates play a pivotal role in propelling market expansion in the region. For instance, data from the Guttmacher Institute in March 2022 revealed that between 2015 and 2019, North America witnessed a total of 5,660,000 pregnancies annually, with 2,590,000 of them being unwanted, and 886,000 resulting in abortion. Moreover, statistics published by the Pew Research Center in June 2022 showed an increase in abortion cases, with 930,160 recorded in the United States in 2020 compared to 916,460 in 2019. This surge in abortion cases is anticipated to drive the demand for various contraceptive methods to prevent unwanted pregnancies, thereby fueling market growth.

Key Market Players

  • Bayer AG
  • Mayer Laboratories Inc
  • Pfizer Inc
  • Mylan Pharmaceuticals Inc
  • Teva Pharmaceutical Industries Ltd
  • Organon & Co.
  • Agile Therapeutics Inc
  • Lupin Pharmaceuticals Inc
  • The Female Health Company
  • FUJI LATEX CO.,LTD.

Report Scope:

In this report, the Global Female Contraceptive Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Female Contraceptive Market, By Contraceptive Drugs:

  • Oral Contraceptives
  • Contraceptive Injections
  • Topical Contraceptives
  • Spermicides

Female Contraceptive Market, By Device:

  • Female Condoms
  • Diaphragms and Caps
  • Vaginal Rings
  • Contraceptive Sponges
  • Sub-dermal Contraceptive Implants
  • Intra Uterine Contraceptive Devices (IUCDs)
  • Others

Female Contraceptive Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Female Contraceptive Market.

Available Customizations:

  • Global Female Contraceptive market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Female Contraceptive Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 5.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2022)
  • 5.3. Product Market Map
    • 5.3.1. By Contraceptive Drugs
    • 5.3.2. By Device
    • 5.3.3. By Region

6. North America Female Contraceptive Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 6.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Female Contraceptive Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Contraceptive Drugs
        • 6.3.1.2.2. By Device
    • 6.3.2. Canada Female Contraceptive Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Contraceptive Drugs
        • 6.3.2.2.2. By Device
    • 6.3.3. Mexico Female Contraceptive Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Contraceptive Drugs
        • 6.3.3.2.2. By Device

7. Europe Female Contraceptive Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 7.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Female Contraceptive Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Contraceptive Drugs
        • 7.3.1.2.2. By Device
    • 7.3.2. United Kingdom Female Contraceptive Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Contraceptive Drugs
        • 7.3.2.2.2. By Device
    • 7.3.3. France Female Contraceptive Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Contraceptive Drugs
        • 7.3.3.2.2. By Device
    • 7.3.4. Italy Female Contraceptive Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Contraceptive Drugs
        • 7.3.4.2.2. By Device
    • 7.3.5. Spain Female Contraceptive Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Contraceptive Drugs
        • 7.3.5.2.2. By Device

8. Asia-Pacific Female Contraceptive Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 8.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 8.2.3. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Female Contraceptive Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Contraceptive Drugs
        • 8.3.1.2.2. By Device
    • 8.3.2. Japan Female Contraceptive Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Contraceptive Drugs
        • 8.3.2.2.2. By Device
    • 8.3.3. India Female Contraceptive Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Contraceptive Drugs
        • 8.3.3.2.2. By Device
    • 8.3.4. Australia Female Contraceptive Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Contraceptive Drugs
        • 8.3.4.2.2. By Device
    • 8.3.5. South Korea Female Contraceptive Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Contraceptive Drugs
        • 8.3.5.2.2. By Device

9. South America Female Contraceptive Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 9.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 9.2.3. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Female Contraceptive Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Contraceptive Drugs
        • 9.3.1.2.2. By Device
    • 9.3.2. Argentina Female Contraceptive Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Contraceptive Drugs
        • 9.3.2.2.2. By Device
    • 9.3.3. Colombia Female Contraceptive Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Contraceptive Drugs
        • 9.3.3.2.2. By Device

10. Middle East and Africa Female Contraceptive Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Contraceptive Drugs (Oral Contraceptives, Contraceptive Injections, Topical Contraceptives, Spermicides)
    • 10.2.2. By Device (Female Condoms, Diaphragms and Caps, Vaginal Rings, Contraceptive Sponges, Sub-dermal Contraceptive Implants, Intra Uterine Contraceptive Devices (IUCDs), Others)
    • 10.2.3. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Female Contraceptive Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Contraceptive Drugs
        • 10.3.1.2.2. By Device
    • 10.3.2. Saudi Arabia Female Contraceptive Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Contraceptive Drugs
        • 10.3.2.2.2. By Device
    • 10.3.3. UAE Female Contraceptive Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Contraceptive Drugs
        • 10.3.3.2.2. By Device
    • 10.3.4. Kuwait Female Contraceptive Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Contraceptive Drugs
        • 10.3.4.2.2. By Device

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Development
  • 12.2. Mergers & Acquisitions
  • 12.3. Product Launches

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Business Overview
  • 14.2. Product Offerings
  • 14.3. Recent Developments
  • 14.4. Financials (As Reported)
  • 14.5. Key Personnel
  • 14.6. SWOT Analysis
    • 14.6.1. Bayer AG
    • 14.6.2. Mayer Laboratories Inc
    • 14.6.3. Pfizer Inc
    • 14.6.4. Mylan Pharmaceuticals Inc
    • 14.6.5. Teva Pharmaceutical Industries Ltd
    • 14.6.6. Organon & Co.
    • 14.6.7. Agile Therapeutics Inc
    • 14.6.8. Lupin Pharmaceuticals Inc
    • 14.6.9. The Female Health Company
    • 14.6.10. FUJI LATEX CO.,LTD.

15. Strategic Recommendations

16. About Us & Disclaimer